Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].

Michel L, Lions C, Winnock M, Lang JP, Loko MA, Rosenthal E, Marchou B, Valantin MA, Morlat P, Roux P, Sogni P, Spire B, Poizot-Martin I, Lacombe K, Lascoux-Combe C, Duvivier C, Neau D, Dabis F, Salmon-Ceron D, Carrieri MP; ANRS HEPAVIH CO13 study group..

HIV Med. 2016 Nov;17(10):758-765. doi: 10.1111/hiv.12382.

PMID:
27187027
2.

Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.

Nasta P, Salmon D, d'Arminio Monforte A, Pimenta JM, Cerini C, Giralda M, Winnock M, Cozzi-Lepri A.

HIV Clin Trials. 2016 May;17(3):96-108. doi: 10.1080/15284336.2016.1150409.

PMID:
27125364
3.

Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group..

Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217.

4.

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.

Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; ESCMID European Study Group on Viral Hepatitis..

Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799.

PMID:
25650873
5.

Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.

Marcellin F, Roux P, Winnock M, Lions C, Dabis F, Salmon-Ceron D, Loko MA, Spire B, Carrieri MP.

Expert Rev Gastroenterol Hepatol. 2014 May;8(4):351-8. doi: 10.1586/17474124.2014.888949. Review.

PMID:
24580042
6.

Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.

Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, Duvivier C, Bouchaud O, Gervais A, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group..

AIDS. 2014 May 15;28(8):1155-60. doi: 10.1097/QAD.0000000000000218.

PMID:
24499953
7.

Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.

Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH Study Group..

Antivir Ther. 2014;19(2):171-8. doi: 10.3851/IMP2699.

8.

Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.

Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D.

HIV Med. 2014 Jan;15(1):30-9. doi: 10.1111/hiv.12082.

9.

Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.

Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group..

J Hepatol. 2014 Jan;60(1):46-53. doi: 10.1016/j.jhep.2013.08.014.

PMID:
23978720
10.

Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.

Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, Morlat P, Marchou B, Dabis F, Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group..

HIV Med. 2013 Aug;14(7):430-6. doi: 10.1111/hiv.12023.

11.

Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).

Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, Mora M, Loko MA, Dabis F, Dominguez S, Roux P, Carrieri MP; ANRS CO13 HEPAVIH Study Group..

Addiction. 2013 Jul;108(7):1250-8. doi: 10.1111/add.12149.

PMID:
23421419
12.

HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.

Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, Trimoulet P, Dabis F, Salmon-Ceron D, Izopet J; ANRS CO13 HEPAVIH Study Group..

PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289.

13.

Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.

Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group..

Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419.

PMID:
23052829
14.

Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?

Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G; ANRS CO-13 HEPAVIH Study Group..

AIDS. 2012 Nov 13;26(17):2193-9. doi: 10.1097/QAD.0b013e32835763a4.

PMID:
22781224
15.

Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13).

Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B; HEPAVIH Study Group..

Hepatology. 2012 Nov;56(5):2010. doi: 10.1002/hep.25813. No abstract available.

PMID:
22535683
16.

Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).

Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group..

BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59.

17.

Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?

Trimoulet P, Merchadou L, Winnock M, Loko MA, Fleury H, Salmon D, Dabis F, Neau D; ANRS CO 13 HEPAVIH Study Group..

J Virol Methods. 2012 Apr;181(1):131-3. doi: 10.1016/j.jviromet.2012.01.006.

PMID:
22285372
18.

Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).

Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group.; ANRS CO12 Cirvir study group..

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):214-21. doi: 10.1016/j.clinre.2011.11.002.

PMID:
22189509
19.

Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.

Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P.

J Hepatol. 2012 Apr;56(4):862-8. doi: 10.1016/j.jhep.2011.11.009.

PMID:
22173166
20.

Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination.

Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Lascoux-Combe C, Garipuy D, Rosenthal E, Carrieri P, Dabis F, Salmon D.

Vaccine. 2011 Nov 3;29(47):8656-60. doi: 10.1016/j.vaccine.2011.08.125.

PMID:
21920402
Items per page

Supplemental Content

Loading ...
Support Center